Form 4: ARS Pharmaceuticals Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on April 9, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two tranches of 50,000 shares each, with weighted average sales prices of $9.2777 and $9.277 per share.
• Following the transactions, Tanimoto directly owns 3,276,854 shares.
• Tanimoto also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust, as well as shares held by her spouse.
• The filing indicates that Tanimoto disclaims beneficial ownership of shares held by the Richard Lowenthal Charitable Remainder UniTrust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an insider. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. Rule 10b5-1 plans are commonly used by corporate insiders to sell shares over time to avoid accusations of trading on non-public information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates